United States
|
|||
Securities and Exchange Commission
|
|||
Washington, D.C. 20549
|
|||
FORM 8-K
|
|||
Current Report Pursuant to
|
|||
Section 13 or 15(d) of the Securities Exchange Act of 1934
|
|||
August 2, 2012
|
|||
(Date of Report)
|
|||
ULTRALIFE CORPORATION
|
|||
(Exact name of registrant as specified in its charter)
|
|||
Delaware
|
000-20852
|
16-1387013
|
|
(State of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
2000 Technology Parkway, Newark, New York
|
14513
|
||
(Address of principal executive offices)
|
(Zip Code)
|
||
(315) 332-7100
|
|||
(Registrant’s telephone number, including area code)
|
|||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|||
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|||
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|||
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|||
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|||
Item 2.02
|
Results of Operation and Financial Condition.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d)
|
Exhibits. The following exhibit is being furnished as part of this Report.
|
Exhibit
Number |
Description
|
99.1
|
Press Release of Ultralife Corporation dated August 2, 2012
|
Date: August 2, 2012
|
ULTRALIFE CORPORATION
|
|
By:
|
/s/ Peter F. Comerford
|
|
Peter F. Comerford
|
||
Vice President of Administration and
|
||
General Counsel
|
Exhibit
Number
|
Description
|
99.1
|
Press Release of Ultralife Corporation dated August 2, 2012
|
Company Contact:
Ultralife Corporation
Philip Fain
(315) 332-7100
pfain@ulbi.com
|
Investor Relations Contact:
Lippert/Heilshorn & Associates
Jody Burfening
(212) 838-3777
jburfening@lhai.com
|
ULTRALIFE CORPORATION
|
||||||||||||||||
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
|
||||||||||||||||
(In Thousands, Except Per Share Amounts)
|
||||||||||||||||
(Unaudited)
|
||||||||||||||||
Three-Month Periods Ended
|
Six-Month Periods Ended
|
|||||||||||||||
July 1,
|
July 3,
|
July 1,
|
July 3,
|
|||||||||||||
2012
|
2011
|
2012
|
2011
|
|||||||||||||
Revenues:
|
||||||||||||||||
Battery & energy products
|
$ | 15,523 | $ | 31,239 | $ | 35,605 | $ | 55,487 | ||||||||
Communications systems
|
3,183 | 11,873 | 10,602 | 15,540 | ||||||||||||
Total revenues
|
18,706 | 43,112 | 46,207 | 71,027 | ||||||||||||
Cost of products sold:
|
||||||||||||||||
Battery & energy products
|
11,760 | 23,986 | 27,899 | 45,193 | ||||||||||||
Communications systems
|
2,479 | 7,566 | 7,248 | 9,860 | ||||||||||||
Total cost of products sold
|
14,239 | 31,552 | 35,147 | 55,053 | ||||||||||||
Gross profit
|
4,467 | 11,560 | 11,060 | 15,974 | ||||||||||||
Operating expenses:
|
||||||||||||||||
Research and development
|
1,970 | 2,114 | 4,109 | 4,619 | ||||||||||||
Selling, general, and administrative
|
5,429 | 6,409 | 11,172 | 12,254 | ||||||||||||
Total operating expenses
|
7,399 | 8,523 | 15,281 | 16,873 | ||||||||||||
Operating income (loss)
|
(2,932 | ) | 3,037 | (4,221 | ) | (899 | ) | |||||||||
Other income (expense):
|
||||||||||||||||
Interest income
|
2 | 1 | 3 | 2 | ||||||||||||
Interest expense
|
(115 | ) | (162 | ) | (219 | ) | (318 | ) | ||||||||
Miscellaneous
|
(20 | ) | (9 | ) | 32 | 290 | ||||||||||
Income (loss) from continuing operations before income taxes
|
(3,065 | ) | 2,867 | (4,405 | ) | (925 | ) | |||||||||
|
||||||||||||||||
Income tax provision-current
|
188 | 63 | 267 | 67 | ||||||||||||
Income tax provision (benefit)-deferred
|
(17 | ) | 55 | (5 | ) | 109 | ||||||||||
Total income taxes
|
171 | 118 | 262 | 176 | ||||||||||||
Net income (loss) from continuing operations
|
(3,236 | ) | 2,749 | (4,667 | ) | (1,101 | ) | |||||||||
Discontinued operations:
|
||||||||||||||||
Income (loss) from discontinued operations, net of tax
|
49 | (2,325 | ) | (22 | ) | (4,178 | ) | |||||||||
Net income (loss)
|
(3,187 | ) | 424 | (4,689 | ) | (5,279 | ) | |||||||||
Net (income) loss attributable to noncontrolling interest
|
20 | 15 | 20 | 28 | ||||||||||||
Net income (loss) attributable to Ultralife
|
$ | (3,167 | ) | $ | 439 | $ | (4,669 | ) | $ | (5,251 | ) | |||||
Other comprehensive income (loss):
|
||||||||||||||||
Foreign currency translation adjustments
|
(25 | ) | 60 | 123 | 287 | |||||||||||
Comprehensive income (loss) attributable to Ultralife
|
$ | (3,192 | ) | $ | 499 | $ | (4,546 | ) | $ | (4,964 | ) | |||||
Net income (loss) attributable to Ultralife common shareholders - basic
|
||||||||||||||||
Continuing operations
|
$ | (0.18 | ) | $ | 0.16 | $ | (0.27 | ) | $ | (0.06 | ) | |||||
Discontinued operations
|
$ | 0.00 | $ | (0.13 | ) | $ | (0.00 | ) | $ | (0.24 | ) | |||||
Total
|
$ | (0.18 | ) | $ | 0.03 | $ | (0.27 | ) | $ | (0.30 | ) | |||||
Net income (loss) attributable to Ultralife common shareholders - diluted
|
||||||||||||||||
Continuing operations
|
$ | (0.18 | ) | $ | 0.16 | $ | (0.27 | ) | $ | (0.06 | ) | |||||
Discontinued operations
|
$ | 0.00 | $ | (0.13 | ) | $ | (0.00 | ) | $ | (0.24 | ) | |||||
Total
|
$ | (0.18 | ) | $ | 0.03 | $ | (0.27 | ) | $ | (0.30 | ) | |||||
Weighted average shares outstanding - basic
|
17,396 | 17,296 | 17,376 | 17,286 | ||||||||||||
Weighted average shares outstanding - diluted
|
17,396 | 17,308 | 17,376 | 17,286 |
ULTRALIFE CORPORATION
|
||||||||
CONSOLIDATED BALANCE SHEETS
|
||||||||
(In Thousands, Except Per Share Amounts)
|
||||||||
(unaudited)
|
||||||||
July 1,
|
December 31,
|
|||||||
ASSETS
|
2012
|
2011
|
||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$ | 4,178 | $ | 5,486 | ||||
Trade accounts receivable, net
|
15,611 | 19,903 | ||||||
Inventories
|
33,692 | 34,967 | ||||||
Prepaid expenses and other current assets
|
3,025 | 3,877 | ||||||
Total current assets
|
56,506 | 64,233 | ||||||
Property and equipment
|
12,714 | 12,588 | ||||||
Other assets:
|
||||||||
Goodwill, intangible and other assets
|
23,771 | 23,994 | ||||||
Total Assets
|
$ | 92,991 | $ | 100,815 | ||||
LIABILITIES AND SHAREHOLDERS' EQUITY
|
||||||||
Current liabilities:
|
||||||||
Short-term debt and current portion of long-term debt
|
$ | 357 | $ | - | ||||
Accounts payable
|
10,748 | 13,766 | ||||||
Other current liabilities
|
7,924 | 9,392 | ||||||
Total current liabilities
|
19,029 | 23,158 | ||||||
Long-term liabilities:
|
||||||||
Other long-term liabilities
|
4,517 | 4,431 | ||||||
Shareholders' equity:
|
||||||||
Ultralife equity:
|
||||||||
Common stock, par value $0.10 per share
|
1,881 | 1,874 | ||||||
Capital in excess of par value
|
173,087 | 172,309 | ||||||
Accumulated other comprehensive loss
|
(862 | ) | (985 | ) | ||||
Accumulated deficit
|
(96,949 | ) | (92,280 | ) | ||||
|
77,157 | 80,918 | ||||||
Less -- Treasury stock, at cost
|
7,658 | 7,658 | ||||||
Total Ultralife equity
|
69,499 | 73,260 | ||||||
Noncontrolling interest
|
(54 | ) | (34 | ) | ||||
Total shareholders' equity
|
69,445 | 73,226 | ||||||
Total Liabilities and Shareholders' Equity
|
$ | 92,991 | $ | 100,815 |